Caris Life Sciences, Inc. (CAI) Stock Analysis
Healthcare · Biotechnology
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial... Read more
TrendMatrix rates Caris Life Sciences, Inc. (CAI) as Hold with moderate confidence. The stock trades at $18.56 with +50.2% upside to the $27.88 price target. Overall score: 6.2/10 across 10 analysis dimensions. Reward/risk ratio: 5.8:1.
Passes 3/4 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum. Suitability: moderate.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Caris Life Sciences, Inc. (CAI) as Hold with moderate confidence. Score 6.2/10.
Take-profit target: $27.88 (+50.2% upside). Reward/risk ratio: 5.8:1. Stop-loss: $16.97.
Negative momentum.
Caris Life Sciences, Inc. trades at a P/E of N/A (forward 50.3). TrendMatrix value score: 6.5/10. Verdict: Hold.
14 analysts cover CAI with a consensus score of 4.3/5. Average price target: $33.
What does Caris Life Sciences, Inc. do?Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the...
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.